Abstract
Abstract 11354: Role of PCSK9 Inhibitors in Acute Coronary Syndromes - A Pilot Study
Circulation (New York, N.Y.), Vol.146(Suppl_1), pp.A11354-A11354
11/08/2022
DOI: 10.1161/circ.146.suppl_1.11354
Abstract
IntroductionThe proprotein convertase subtilisin/Kexin type 9 (PCSK9) inhibitors have been guideline-approved for intolerant patients to statin therapy or unable to achieve target LDL levels with maximally tolerated therapies. The study aimed to determine whether early initiation of PCSK9 inhibitor with statin therapy in acute coronary syndromes (ACS) patients is beneficial in relation to low-density lipoprotein (LDL) reduction and short-term cardiovascular outcomes. Methods This pilot study included eighty ACS patients randomized to receive either PCSK9 inhibitor (Evolocumab) with statin therapy (n=40) or statin monotherapy (n=40). Patients were followed up for 6 months to assess for LDL levels, left ventricular ejection fraction (LVEF), and major adverse cardiovascular events (MACE) (a composite of myocardial infarction, heart failure, and cardiovascular death). Results Eighty patients with ACS (mean age 59±11 years, 66.3% male) had LDL and LVEF measured at baseline, 3 months, and 6 months. There was no difference between baseline LDL levels (153.1±39.5 vs 146.1±32, p=0.39). LDL levels in PCSK9 inhibitor/statin group were significantly lower at 3 months and 6 months compared to statin monotherapy (76.2±27.7 vs 118.6±31, p<0.0001 and 78.2±22.1 vs 103.7±22.5, p<0.0001, respectively). There was no significant difference between incidences of cardiovascular death (1 vs 3, p=0.31) and MACCE (4 vs 6, p=0.5) between both groups at 6-month follow-up. Conclusion The early initiation of PCSK9 inhibitors/statin combination therapy in ACS patients was associated with a significant reduction of LDL levels at 3 and 6 months yet there was no significant difference in relation to short-term cardiovascular outcomes at a 6-month follow-up. Further research is required to determine whether early initiation of PCSK9 inhibitors in combination with statins or as monotherapy in ACS patients can be associated with improved short or long-term cardiovascular outcomes.
Details
- Title: Subtitle
- Abstract 11354: Role of PCSK9 Inhibitors in Acute Coronary Syndromes - A Pilot Study
- Creators
- Mahmoud Abdelnabi - Cardiology Dept, Texas Tech Univ Health Science Cntr, Lubbock, TXJuthipong Benjanuwattra - Internal Medicine Dept, Texas Tech Univ Health Science Cntr, Lubbock, TXYehia Saleh - Houston MethodistGaspar Del Rio-Pertuz - Internal Medicine Dept, Texas Tech Univ Health Science Cntr, Lubbock, TXNatnicha Leelaviwat - Internal Medicine Dept, Texas Tech Univ Health Sciences Cntr, Lubbock, TXAbdallah Almaghraby - Alexandria University
- Resource Type
- Abstract
- Publication Details
- Circulation (New York, N.Y.), Vol.146(Suppl_1), pp.A11354-A11354
- Publisher
- Lippincott Williams & Wilkins
- DOI
- 10.1161/circ.146.suppl_1.11354
- ISSN
- 0009-7322
- eISSN
- 1524-4539
- Language
- English
- Date published
- 11/08/2022
- Academic Unit
- Internal Medicine
- Record Identifier
- 9984757159202771
Metrics
1 Record Views